GlassScriptPhysician profile
Leslie Lee
NPI 1851591317
$7,170.14
in general payments reported to CMS, 2019-2025
17 companies · $5,557 in 2025
The $5,557 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $134 · 2023: $180 · 2024: $932 · 2025: $5,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,396 · Food and Beverage: $1,776 · Consulting Fee: $330 · Education: $111 · Travel and Lodging: $56.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,396.00 |
| Food and Beverage | $1,775.95 |
| Consulting Fee | $330.00 |
| Education | $111.49 |
| Travel and Lodging | $56.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $5,261.86 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $376.59 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $287.36 | 2021-2025 | |
| Axsome Therapeutics, INC. | $221.80 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $196.66 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $171.93 | 2021-2025 | Rexulti |
| Lundbeck LLC | $146.51 | 2021-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $114.54 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.97 | 2021-2024 | Caplyta |
| Ethicon US, LLC | $65.96 | 2022-2023 | Harmonic |
| Amarin Pharma, INC. | $62.95 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $57.62 | 2021 | |
| Noven Therapeutics, LLC | $34.61 | 2021 | |
| Novo Nordisk INC | $16.59 | 2025 | Ozempic, Rybelsus |
| Amgen INC. | $15.27 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.55 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.